Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 39
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

  • León-Román, Juan
  • Bolufer Cardona, Monica
  • Sánchez-Salinas, Mario
  • Alonso-Martínez, Carla
  • Bestard, Oriol
  • Bermejo García, Sheila
  • Cecilia del Carmen, Carpio Segura
  • Garcia-Carro, Clara
  • Barba, Pere
  • Soler, María José
  • IACOBONI, GLORIA
CAR-T therapy; Acute kidney injury; Onconephrology, Terapia CAR-T; Lesión renal aguda; Onconefrología, Teràpia CAR-T; Lesió renal aguda; Onconefrologia, Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients., P.B. received research funding from the Carlos III Health Institute (PI21/0199,INT23/00072), Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

  • Zamora Carrillo, Jorge Iván
  • Lopez Martinez, Marina
  • Patricio Liebana, Marc
  • León Román, Juan
  • Bermejo Garcia, Sheila
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • Azancot Rivero, M Antonieta
  • Toapanta Gaibor, Nestor Gabriel
  • Gabaldon Dominguez, Alejandra
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
SARS-CoV-2; Immune-mediated glomerulopathy; Vaccine, SARS-CoV-2; Glomerulopatía inmunomediada; Vacuna, SARS-CoV-2; Glomerulopatia immunomediada; Vacuna, Background: Vaccination is a known trigger for the appearance of immune-mediated glomerulopathies (IMG). The appearance of IMG after SARS-CoV-2 vaccination with suspected causality has been described. Our aim is to analyze the incidence of IMG flares before and after SARS-CoV-2 vaccination in our center. Methods: All persons with native kidney biopsy (KB) from January 2019 to March 2022 in our center were included in the study. We compared the incidence of IMG before and after the start of vaccination. We also collected information about whether the patients had received a SARS-CoV-2 vaccine or have suffered from COVID in the six weeks before the IMG. We also evaluated the analytical characteristics of the outbreaks. Results: A total of 386 KB were studied. Of them, 86/218 (39.4%) were IMG performed pre- and 85/168 (50.6%) post-SV (029). The incidence of idiopathic nephrotic syndrome (INS), studied separately, was also significantly increased post-vaccination (n = 18 (10.7%)) compared to pre-vaccination (n = 11 (5%)) (p = 0.036). There were no differences in the incidence of vasculitis or IgA nephropathy. Up to 17 (20%) flares occurred 6 weeks before SARS-CoV-2 vaccination and only 2 (2.4%) within the first 6 weeks after SARS-CoV-2 infection. Within those 17 flares, the most common diagnosis was IgAN (n = 5 (29.4%)); a total of 14 (82.4%) received an mRNA vaccine and 9 (52.9%) took place after the 1st vaccine dose. There were 13 cases of minimal change disease (MCD) with debut/recurrence pre-SV and 20 MCD with debut/recurrence post-SV (p = 0.002). Conclusions: The incidence of IMG, INS and MCD flares in our center increased significantly after SARS-CoV-2 vaccination. Importantly, 20% of IMG flares took place within the first 6 weeks after receiving a vaccine dose, with the first dose being the riskiest one and IgAN the most frequent diagnosis., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant numbers PI17/00257, PI21/01292, RICORS RD21/0005/0016, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A predictive model of non-diabetic kidney disease in patients with diabetes mellitus and chronic kidney disease. A Spanish multi-center study, Modelo predictivo de enfermedad renal no diabética en los pacientes con diabetes mellitus y enfermedad renal crónica. Un estudio multicéntrico español

  • González Monte, Esther
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López Espinosa, Diana
  • MARTIN-GÓMEZ, ADORACIÓN
  • Bermejo García, Sheila
  • Agraz Pamplona, Irene
  • Soler, María José
Kidney biopsy; Diabetes mellitus; Chronic kidney disease, Biopsia renal; Diabetes mellitus; Enfermedad renal crónica, Biòpsia renal; Diabetis mellitus; Malaltia renal crònica, Aims Kidney biopsy is increasing in patients with diabetes and around 50–60% of patients with diabetes have non-diabetic kidney disease (NDKD). Identifying NDKD is crucial since these patients have a better renal prognosis and survival compared to patients with diabetic nephropathy (DN). The objective of this study is to provide a clinical practice tool for through a predictive model of NDKD. Material and methods Observational and multicenter Spanish study of the pathological results of kidney biopsies in patients with diabetes from 2002 to 2014. A logistic regression analysis and the probability of presenting NDKD was calculated using a punctuation score. Results A total of 832 patients with diabetes and renal biopsy were analyzed. An accurate risk-predictive model for NDKD was developed with five top-ranked non-invasive clinical variables (age, serum creatinine, presence of diabetic retinopathy, microhematuria and peripheral vascular disease) obtaining a score for each one allowing for a proper prediction of NDKD. Conclusions In our study, we developed a risk-stratification score to calculate the probability of NDKD. This could be in a next future a useful tool for the clinical indication of renal biopsy in patients with diabetes and kidney disease., La realización de la biopsia renal está aumentando en los pacientes diabéticos, diagnosticándose entre el 50-60% de nefropatía no-diabética (NND). Este hecho es crucial dado que se ha demostrado una mejor supervivencia y pronóstico renal en la NND comparado con la nefropatía diabética (ND). El objetivo de este estudio es proporcionar una herramienta de práctica clínica a través de un modelo predictivo de NND. Material y métodos Estudio observacional multicéntrico español del resultado anatomo-patológico en los pacientes con diabetes y biopsia renal desde 2002 hasta el 2014. Un análisis de regresión logística y la probabilidad de presentar NND fue calculada mediante una puntuación obtenida. Resultados Un total de 832 pacientes fueron analizados. Se desarrolló un modelo predictivo de riesgo certero para la NND con 5 variables clínicas (edad, creatinina, presencia de retinopatía diabética, microhematuria y enfermedad vascular periférica) obteniendo una puntuación para cada una que permite una predicción adecuada de NND. Conclusiones En nuestro estudio, desarrollamos una puntuación de estratificación de riesgo para calcular la probabilidad de NND. Esto podría ser en un futuro próximo una herramienta útil para la indicación clínica de biopsia renal en los pacientes con diabetes y enfermedad renal., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI21/01292, PI20/00744, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, BECA SENFRO 2021 and RD21/0005/0016 (RICORS 2040).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Endothelin Receptor Antagonists in Kidney Disease

  • Martinez Diaz, Irene
  • Martos Guillamé, Nerea
  • Llorens Cebriá, Carmen
  • Álvarez, Francisco J.
  • Bedard, Patricia W.
  • Vergara Arana, Ander
  • Jacobs Cachá, Concepció
  • Soler Romeo, Maria Jose
Atrasentan; Endothelin; Kidney disease, Atrasentan; Endotelina; Nefropatía, Atrasentan; Endotelina; Nefropatia, Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ETA) activation, causes sustained vasoconstriction of the afferent arterioles that produces deleterious effects such as hyperfiltration, podocyte damage, proteinuria and, eventually, GFR decline. Therefore, endothelin receptor antagonists (ERAs) have been proposed as a therapeutic strategy to reduce proteinuria and slow the progression of kidney disease. Preclinical and clinical evidence has revealed that the administration of ERAs reduces kidney fibrosis, inflammation and proteinuria. Currently, the efficacy of many ERAs to treat kidney disease is being tested in randomized controlled trials; however, some of these, such as avosentan and atrasentan, were not commercialized due to the adverse events related to their use. Therefore, to take advantage of the protective properties of the ERAs, the use of ETA receptor-specific antagonists and/or combining them with sodium-glucose cotransporter 2 inhibitors (SGLT2i) has been proposed to prevent oedemas, the main ERAs-related deleterious effect. The use of a dual angiotensin-II type 1/endothelin receptor blocker (sparsentan) is also being evaluated to treat kidney disease. Here, we reviewed the main ERAs developed and the preclinical and clinical evidence of their kidney-protective effects. Additionally, we provided an overview of new strategies that have been proposed to integrate ERAs in kidney disease treatment., The authors have funding from Fondo de Investigación Sanitaria-Feder, ISCIII, PI21/01292, RICORS RD21/0005/0031, and Marató TV3 421/C/2020, Marató TV3 759/U/2020, Marató TV3 215/C/2021.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
  • Barreira Diaz, Ana
  • Bermejo Garcia, Sheila
  • Suarez-Almazor, Maria
  • Bruera, Sebastian
Acute kidney injury; Immune checkpoint inhibitors; Immune-related hepatitis, Lesión renal aguda; Inhibidores del punto de control inmunitario; Hepatitis relacionada con el sistema inmunitario, Lesió renal aguda; Inhibidors del punt de control immunitari; Hepatitis associada a la immunitat, There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2–3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN (grant numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016) and Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR) enfermedades glomerulares complejas. Supported in part by the University of Texas MD Anderson’s Cancer Center Support Grant from the National Cancer Institute (NCI P30 CA016672).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

  • Bermejo Garcia, Sheila
  • Bolufer Cardona, Monica
  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
Chronic kidney disease; Dialysis; Immunotherapy, Enfermedad renal cronica; Diálisis; Inmunoterapia, Malaltia renal crònica; Diàlisi; Immunoteràpia, The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Obesity-Related Kidney Disease: A Growing Threat to Renal Health

  • León-Román, Juan
  • Esteves, Alexandra
  • Alvarez, Tiffany
  • López-Martínez, Marina
  • Ciudin Mihai, Andreea
  • Núñez Delgado, Sara
  • Soler, María José
  • Lecube, Albert
Cardiovascular disease; Kidney disease; Obesity, Malaltia cardiovascular; Malaltia renal; Obesitat, Enfermedad cardiovascular; Enfermedad renal; Obesidad, Obesity represents a serious and growing disease worldwide. The pathophysiological changes secondary to chronic inflammation lead to the development of diseases that increase the morbidity and mortality of individuals. Chronic kidney disease (CKD) is a condition with deleterious effects that acts bidirectionally with obesity. From approximately 20% to 30% of individuals share phenotypes of CKD and obesity, increasing their cardiovascular risk and the risk of other complications. Obesity and CKD form a vicious cycle in which inflammation is the central axis of multiorgan damage. Despite increasing the risk of cardiac and renal mortality, CKD progresses in relation to body mass index and albuminuria. Nowadays, the implementation of the new medications aimed at mitigating the peak of inflammation is becoming a cornerstone of treatments for obesity, diabetes, cardiovascular diseases, and renal disease., This research was funded by, ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292 and PI24/00852, INT24/00067, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016, RD24/0004/0031. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study

  • Bolufer Cardona, Monica
  • Blasco, Miquel
  • Quintana, Luis F
  • Rabasco, Cristina
  • Shabaka, Amir
  • García-Carro, Clara
Kidney biopsy; Renal pathology; Solid organ neoplasm, Biòpsia renal; Patologia renal; Neoplàsia d'òrgans sòlids, Biopsia renal; Patología renal; Neoplasia de órganos sólidos, Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, Río Hortega CM20/00111, PI17/00257, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, and RD21/0005/0016 (RICORS 2040).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units

  • León-Román, Juan
  • Azancot Rivero, M Antonieta
  • Marouço, Catarina
  • Patricio-Liébana, Marc
  • Ramos Terrades, Natalia
  • Núñez Delgado, Sara
  • Zamora Carrillo, Jorge Ivan
  • TOAPANTA, NÉSTOR
  • Méndez Fernández, Ana Belén
  • Soler, María José
Cardiorenal syndrome; Chronic kidney disease; Heart failure, Síndrome cardiorrenal; Enfermedad renal crónica; Insuficiencia cardíaca, Síndrome cardiorenal; Malaltia renal crònica; Insuficiència cardíaca, Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this study is to evaluate the clinical performance of patients with CRS who are followed up by the Cardiorenal Unit (CRU). Methods: We conducted a retrospective observational study of patients referred to the CRU from April 1, 2022, to April 30, 2023. Demographics, laboratory and ultrasonographic tests, and outcomes were evaluated. Results: Fifty-four patients were seen in the CRU. A total of 45 (83%) and 16 (30%) patients completed follow-up in the CRU at 6 and 12 months, respectively. The mean age was 70 years ± 1.6, and 65% were men. Almost 50% of patients had ischemic heart disease-related HF. The mean cardiac ejection fraction (EF) was 40% ± 1.6, and 61% of patients had HF with reduced EF (HFrEF). NYHA functional classes II and III were the most frequent (60% and 35%, respectively). At 6 months after follow-up, treatment was optimized with sacubitril-valsartan in 33% vs. 49% (p = 0.02) and SGLT2 inhibitors in 48% vs. 72% (p = 0.008), without significant deterioration in renal function (creatinine: p = 0.61; eGFR: p = 0.19). There was also a reduction of more than 50% in the number of hospital admissions (p = 0.002). A total of 22% required peritoneal dialysis, and 20% required hemodialysis. Ten (19%) patients died, five of them due to cardiovascular (CV) events. Conclusions: The CRU is vital for the management of complex patients as it ensures the implementation of medications that reduce CV mortality and decrease the number of hospital admissions in HF., This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, Grant No. PI21/01292, PI24/01510, ERA PerMed JTC2022 Grant No. AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas, PI23/01209 Proyectos de I+D+I en Salud AES2023.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy

  • Martín Agramunt, Maria
  • Llorens Cebrià, Carmen
  • León-Román, Juan
  • Pérez Beltran, Víctor
  • Saumell, Silvia
  • Torres, Irina B.
  • López González, Mercedes
  • Perurena-Prieto, Janire
  • Agraz Pamplona, Irene
  • Sellarès , Joana
  • Ramos Terrades, Natalia
  • Bestard, Oriol
  • Moreso, Francesc
  • Ariceta Iraola, Gema
  • Soler, María José
  • Hernandez-Gonzalez, Manuel
  • Jacobs-Cacha, Conxita
Biomarkers; C5 blockade; Complement system, Biomarcadors; Bloqueig C5; Sistema del complement, Biomarcadores; Bloqueo C5; Sistema del complemento, Introduction Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing aHUS. There is no gold standard test to monitor disease activity; however, the ex vivo C5b-9 deposition test seems to be a good approach. Methods We assessed the C5b-9 deposition induced by serum samples of patients with aHUS (n = 8) and with TMA associated with kidney (n = 2), lung (n = 1) or hematopoietic stem cell (HSC) transplantation (HSCT, n = 2) during the acute phase of the disease or in remission. As control for transplant-associated TMA (TA-TMA), we analyzed samples of clinically stable kidney and HSC-transplanted patients without signs of TMA. In addition, we studied 1 child with genetic risk of aHUS during an acute infection. Results In the acute disease phase or in patients with disease activity despite C5 blockade, a significant increase of C5b-9 deposition was detected. In all patients with clinical response to C5 blockade but one, levels of C5b-9 deposition were within the normal range. Finally, we detected increased C5b-9 deposition levels in an asymptomatic child with genetic risk of aHUS when a concomitant otitis episode was ongoing. Conclusion The ex vivo C5b-9 deposition test is an auspicious tool to monitor CS activity in aHUS and TA-TMA. In addition, we demonstrate that the test may be useful to detect subclinical increase of CS activity, which expands the spectrum of patients that would benefit from a better CS activity assessment., This study was funded with a research grant from Alexion and a grant from the Spanish Society of Nephrology. JL-R is recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM23/00213). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292), Fundació la Marató de TV3 (202017-10, 202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

  • León Román, Juan
  • Agraz Pamplona, Irene
  • Vergara Arana, Ander
  • Toapanta Gaibor, Nestor Gabriel
  • García Carro, Clara
  • Gabaldon Dominguez, Alejandra
  • Roxana Bury Macias, Roxana Paola
  • Bermejo Garcia, Sheila
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
COVID-19; Nefritis tubulointersticial aguda; Biòpsia de ronyó, COVID-19; Nefritis tubulointersticial aguda; Biopsia de riñón, COVID-19; Acute tubulointerstitial nephritis; Kidney biopsy, Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the ‘novo’ GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant number PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS)

  • Núñez-Seral, Norberto
  • Martínez Díaz, Irene
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Villena-Ortiz, Yolanda
  • Soler, María José
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
Apolipoproteína; Cromatografía líquida; Espectrometría de masas, Apolipoprotein; Liquid chromatography; Mass spectrometry, Apolipoproteïna; Cromatografia líquida; Espectrometria de masses, Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist., C.L.C. performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. We thank Mandy Rettel from the PCF of EMBL for technical assistance. The study was funded with a grant from Fundació la Marató de TV3 (ref 202017-10). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292) and Fundació la Marató de TV3 (202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, drug delivery, and therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events, Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bruera, Sebastian
  • Suarez-Almazor, Maria E.
There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2-3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease, Should We Individualize the Treatment?

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bolufer, Mónica|||0000-0002-3379-7031
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • González, Ester
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López, Diana
  • Martín-Gómez, Adoración
  • Garcia-Osuna, Rosa
  • Linares, Tania
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Martín, Nàdia
  • Barros, Xoana|||0000-0001-9690-9769
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Esparza, Noemí
  • Elias, Sandra
  • Coloma, Ana|||0000-0002-1773-9560
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Poch, Esteban|||0000-0002-6492-024X
  • Rodas, Lidia
  • Lozano, Víctor
  • Fernández-Fernández, Beatriz
  • Hernández, Eduardo
  • Martínez, Maria Isabel
  • Stanescu, Ramona Ionela
  • Moirón, José Pelayo
  • García Fernández, Nuria|||0000-0003-1082-0806
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Calero, Francesca|||0000-0002-5758-0769
  • Bonet Sol, Josep
  • Liaño, Fernando
  • Pascual, Julio|||0000-0002-4735-7838
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
  • Praga, Manuel|||0000-0001-9270-1071
  • Fulladosa, Xavier|||0000-0003-1974-9874
  • Soler, María José|||0000-0003-3621-0766
Up to 50-60% of patients with diabetes have non-diabetic kidney disease (NDKD) on kidney biopsy. Diabetic retinopathy (DR) is a microvascular complication of diabetes frequently associated with diabetic nephropathy (DN). The objective of the current study was to investigate the kidney outcomes and survival in patients with biopsy diagnoses of DN and NDKD according to the presence of DR. We conducted an observational, multicentre and retrospective study of the pathological findings of renal biopsies from 832 consecutive patients with diabetes from 2002 to 2014 from 18 nephrology departments. The association of DR with kidney replacement therapy (KRT) or survival was assessed by Kaplan-Meier and Cox regression analyses. Of 832 patients with diabetes and renal biopsy, 768 had a retinal examination and 221/768 (22.6%) had DR. During a follow-up of 10 years, 288/760 (37.9%) patients with follow-up data needed KRT and 157/760 (20.7%) died. The incidence of KRT was higher among patients with DN (alone or with NDKD) and DR [103/175 (58.9%)] than among patients without DR [88/216 (40.7%), P <.0001]. The incidence of KRT was also higher among patients with only NDKD and DR than among those without DR [18/46 (39.1%) versus 79/331 (23.9%), P <.0001]. In multivariate analysis, DR or DN were independent risk factors for KRT {hazard ratio [HR] 2.48 [confidence interval (CI) 1.85-3.31], P <.001}. DN (with or without DR) was also identified as an independent risk factor for mortality [HR 1.81 (CI 1.26-2.62), P =.001]. DR is associated with a higher risk of progression to kidney failure in patients with histological DN and in patients with NDKD.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy

  • Martín Agramunt, Maria
  • Llorens Cebrià, Carmen
  • León-Román, Juan
  • Pérez Beltran, Víctor
  • Saumell, Silvia
  • Torres, Irina B.
  • López González, Mercedes
  • Perurena-Prieto, Janire
  • Agraz Pamplona, Irene
  • Sellarès , Joana
  • Ramos Terrades, Natalia
  • Bestard, Oriol
  • Moreso, Francesc
  • Ariceta Iraola, Gema
  • Soler, María José
  • Hernandez-Gonzalez, Manuel
  • Jacobs-Cacha, Conxita
Biomarkers; C5 blockade; Complement system, Biomarcadors; Bloqueig C5; Sistema del complement, Biomarcadores; Bloqueo C5; Sistema del complemento, Introduction Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing aHUS. There is no gold standard test to monitor disease activity; however, the ex vivo C5b-9 deposition test seems to be a good approach. Methods We assessed the C5b-9 deposition induced by serum samples of patients with aHUS (n = 8) and with TMA associated with kidney (n = 2), lung (n = 1) or hematopoietic stem cell (HSC) transplantation (HSCT, n = 2) during the acute phase of the disease or in remission. As control for transplant-associated TMA (TA-TMA), we analyzed samples of clinically stable kidney and HSC-transplanted patients without signs of TMA. In addition, we studied 1 child with genetic risk of aHUS during an acute infection. Results In the acute disease phase or in patients with disease activity despite C5 blockade, a significant increase of C5b-9 deposition was detected. In all patients with clinical response to C5 blockade but one, levels of C5b-9 deposition were within the normal range. Finally, we detected increased C5b-9 deposition levels in an asymptomatic child with genetic risk of aHUS when a concomitant otitis episode was ongoing. Conclusion The ex vivo C5b-9 deposition test is an auspicious tool to monitor CS activity in aHUS and TA-TMA. In addition, we demonstrate that the test may be useful to detect subclinical increase of CS activity, which expands the spectrum of patients that would benefit from a better CS activity assessment., This study was funded with a research grant from Alexion and a grant from the Spanish Society of Nephrology. JL-R is recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM23/00213). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292), Fundació la Marató de TV3 (202017-10, 202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A predictive model of non-diabetic kidney disease in patients with diabetes mellitus and chronic kidney disease. A Spanish multi-center study, Modelo predictivo de enfermedad renal no diabética en los pacientes con diabetes mellitus y enfermedad renal crónica. Un estudio multicéntrico español

  • González Monte, Esther
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López Espinosa, Diana
  • MARTIN-GÓMEZ, ADORACIÓN
  • Bermejo García, Sheila
  • Agraz Pamplona, Irene
  • Soler, María José
Kidney biopsy; Diabetes mellitus; Chronic kidney disease, Biopsia renal; Diabetes mellitus; Enfermedad renal crónica, Biòpsia renal; Diabetis mellitus; Malaltia renal crònica, Aims Kidney biopsy is increasing in patients with diabetes and around 50–60% of patients with diabetes have non-diabetic kidney disease (NDKD). Identifying NDKD is crucial since these patients have a better renal prognosis and survival compared to patients with diabetic nephropathy (DN). The objective of this study is to provide a clinical practice tool for through a predictive model of NDKD. Material and methods Observational and multicenter Spanish study of the pathological results of kidney biopsies in patients with diabetes from 2002 to 2014. A logistic regression analysis and the probability of presenting NDKD was calculated using a punctuation score. Results A total of 832 patients with diabetes and renal biopsy were analyzed. An accurate risk-predictive model for NDKD was developed with five top-ranked non-invasive clinical variables (age, serum creatinine, presence of diabetic retinopathy, microhematuria and peripheral vascular disease) obtaining a score for each one allowing for a proper prediction of NDKD. Conclusions In our study, we developed a risk-stratification score to calculate the probability of NDKD. This could be in a next future a useful tool for the clinical indication of renal biopsy in patients with diabetes and kidney disease., La realización de la biopsia renal está aumentando en los pacientes diabéticos, diagnosticándose entre el 50-60% de nefropatía no-diabética (NND). Este hecho es crucial dado que se ha demostrado una mejor supervivencia y pronóstico renal en la NND comparado con la nefropatía diabética (ND). El objetivo de este estudio es proporcionar una herramienta de práctica clínica a través de un modelo predictivo de NND. Material y métodos Estudio observacional multicéntrico español del resultado anatomo-patológico en los pacientes con diabetes y biopsia renal desde 2002 hasta el 2014. Un análisis de regresión logística y la probabilidad de presentar NND fue calculada mediante una puntuación obtenida. Resultados Un total de 832 pacientes fueron analizados. Se desarrolló un modelo predictivo de riesgo certero para la NND con 5 variables clínicas (edad, creatinina, presencia de retinopatía diabética, microhematuria y enfermedad vascular periférica) obteniendo una puntuación para cada una que permite una predicción adecuada de NND. Conclusiones En nuestro estudio, desarrollamos una puntuación de estratificación de riesgo para calcular la probabilidad de NND. Esto podría ser en un futuro próximo una herramienta útil para la indicación clínica de biopsia renal en los pacientes con diabetes y enfermedad renal., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI21/01292, PI20/00744, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, BECA SENFRO 2021 and RD21/0005/0016 (RICORS 2040).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Obesity-Related Kidney Disease: A Growing Threat to Renal Health

  • León-Román, Juan
  • Esteves, Alexandra
  • Alvarez, Tiffany
  • López-Martínez, Marina
  • Ciudin Mihai, Andreea
  • Núñez Delgado, Sara
  • Soler, María José
  • Lecube, Albert
Cardiovascular disease; Kidney disease; Obesity, Malaltia cardiovascular; Malaltia renal; Obesitat, Enfermedad cardiovascular; Enfermedad renal; Obesidad, Obesity represents a serious and growing disease worldwide. The pathophysiological changes secondary to chronic inflammation lead to the development of diseases that increase the morbidity and mortality of individuals. Chronic kidney disease (CKD) is a condition with deleterious effects that acts bidirectionally with obesity. From approximately 20% to 30% of individuals share phenotypes of CKD and obesity, increasing their cardiovascular risk and the risk of other complications. Obesity and CKD form a vicious cycle in which inflammation is the central axis of multiorgan damage. Despite increasing the risk of cardiac and renal mortality, CKD progresses in relation to body mass index and albuminuria. Nowadays, the implementation of the new medications aimed at mitigating the peak of inflammation is becoming a cornerstone of treatments for obesity, diabetes, cardiovascular diseases, and renal disease., This research was funded by, ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292 and PI24/00852, INT24/00067, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016, RD24/0004/0031. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

  • Bermejo Garcia, Sheila
  • Bolufer Cardona, Monica
  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
Chronic kidney disease; Dialysis; Immunotherapy, Enfermedad renal cronica; Diálisis; Inmunoterapia, Malaltia renal crònica; Diàlisi; Immunoteràpia, The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

  • León Román, Juan
  • Agraz Pamplona, Irene
  • Vergara Arana, Ander
  • Toapanta Gaibor, Nestor Gabriel
  • García Carro, Clara
  • Gabaldon Dominguez, Alejandra
  • Roxana Bury Macias, Roxana Paola
  • Bermejo Garcia, Sheila
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
COVID-19; Nefritis tubulointersticial aguda; Biòpsia de ronyó, COVID-19; Nefritis tubulointersticial aguda; Biopsia de riñón, COVID-19; Acute tubulointerstitial nephritis; Kidney biopsy, Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the ‘novo’ GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant number PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

  • Zamora Carrillo, Jorge Iván
  • Lopez Martinez, Marina
  • Patricio Liebana, Marc
  • León Román, Juan
  • Bermejo Garcia, Sheila
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • Azancot Rivero, M Antonieta
  • Toapanta Gaibor, Nestor Gabriel
  • Gabaldon Dominguez, Alejandra
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
SARS-CoV-2; Immune-mediated glomerulopathy; Vaccine, SARS-CoV-2; Glomerulopatía inmunomediada; Vacuna, SARS-CoV-2; Glomerulopatia immunomediada; Vacuna, Background: Vaccination is a known trigger for the appearance of immune-mediated glomerulopathies (IMG). The appearance of IMG after SARS-CoV-2 vaccination with suspected causality has been described. Our aim is to analyze the incidence of IMG flares before and after SARS-CoV-2 vaccination in our center. Methods: All persons with native kidney biopsy (KB) from January 2019 to March 2022 in our center were included in the study. We compared the incidence of IMG before and after the start of vaccination. We also collected information about whether the patients had received a SARS-CoV-2 vaccine or have suffered from COVID in the six weeks before the IMG. We also evaluated the analytical characteristics of the outbreaks. Results: A total of 386 KB were studied. Of them, 86/218 (39.4%) were IMG performed pre- and 85/168 (50.6%) post-SV (029). The incidence of idiopathic nephrotic syndrome (INS), studied separately, was also significantly increased post-vaccination (n = 18 (10.7%)) compared to pre-vaccination (n = 11 (5%)) (p = 0.036). There were no differences in the incidence of vasculitis or IgA nephropathy. Up to 17 (20%) flares occurred 6 weeks before SARS-CoV-2 vaccination and only 2 (2.4%) within the first 6 weeks after SARS-CoV-2 infection. Within those 17 flares, the most common diagnosis was IgAN (n = 5 (29.4%)); a total of 14 (82.4%) received an mRNA vaccine and 9 (52.9%) took place after the 1st vaccine dose. There were 13 cases of minimal change disease (MCD) with debut/recurrence pre-SV and 20 MCD with debut/recurrence post-SV (p = 0.002). Conclusions: The incidence of IMG, INS and MCD flares in our center increased significantly after SARS-CoV-2 vaccination. Importantly, 20% of IMG flares took place within the first 6 weeks after receiving a vaccine dose, with the first dose being the riskiest one and IgAN the most frequent diagnosis., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant numbers PI17/00257, PI21/01292, RICORS RD21/0005/0016, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
  • Barreira Diaz, Ana
  • Bermejo Garcia, Sheila
  • Suarez-Almazor, Maria
  • Bruera, Sebastian
Acute kidney injury; Immune checkpoint inhibitors; Immune-related hepatitis, Lesión renal aguda; Inhibidores del punto de control inmunitario; Hepatitis relacionada con el sistema inmunitario, Lesió renal aguda; Inhibidors del punt de control immunitari; Hepatitis associada a la immunitat, There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2–3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN (grant numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016) and Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR) enfermedades glomerulares complejas. Supported in part by the University of Texas MD Anderson’s Cancer Center Support Grant from the National Cancer Institute (NCI P30 CA016672).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Endothelin Receptor Antagonists in Kidney Disease

  • Martinez Diaz, Irene
  • Martos Guillamé, Nerea
  • Llorens Cebriá, Carmen
  • Álvarez, Francisco J.
  • Bedard, Patricia W.
  • Vergara Arana, Ander
  • Jacobs Cachá, Concepció
  • Soler Romeo, Maria Jose
Atrasentan; Endothelin; Kidney disease, Atrasentan; Endotelina; Nefropatía, Atrasentan; Endotelina; Nefropatia, Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ETA) activation, causes sustained vasoconstriction of the afferent arterioles that produces deleterious effects such as hyperfiltration, podocyte damage, proteinuria and, eventually, GFR decline. Therefore, endothelin receptor antagonists (ERAs) have been proposed as a therapeutic strategy to reduce proteinuria and slow the progression of kidney disease. Preclinical and clinical evidence has revealed that the administration of ERAs reduces kidney fibrosis, inflammation and proteinuria. Currently, the efficacy of many ERAs to treat kidney disease is being tested in randomized controlled trials; however, some of these, such as avosentan and atrasentan, were not commercialized due to the adverse events related to their use. Therefore, to take advantage of the protective properties of the ERAs, the use of ETA receptor-specific antagonists and/or combining them with sodium-glucose cotransporter 2 inhibitors (SGLT2i) has been proposed to prevent oedemas, the main ERAs-related deleterious effect. The use of a dual angiotensin-II type 1/endothelin receptor blocker (sparsentan) is also being evaluated to treat kidney disease. Here, we reviewed the main ERAs developed and the preclinical and clinical evidence of their kidney-protective effects. Additionally, we provided an overview of new strategies that have been proposed to integrate ERAs in kidney disease treatment., The authors have funding from Fondo de Investigación Sanitaria-Feder, ISCIII, PI21/01292, RICORS RD21/0005/0031, and Marató TV3 421/C/2020, Marató TV3 759/U/2020, Marató TV3 215/C/2021.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS)

  • Núñez-Seral, Norberto
  • Martínez Díaz, Irene
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Villena-Ortiz, Yolanda
  • Soler, María José
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
Apolipoproteína; Cromatografía líquida; Espectrometría de masas, Apolipoprotein; Liquid chromatography; Mass spectrometry, Apolipoproteïna; Cromatografia líquida; Espectrometria de masses, Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist., C.L.C. performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. We thank Mandy Rettel from the PCF of EMBL for technical assistance. The study was funded with a grant from Fundació la Marató de TV3 (ref 202017-10). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292) and Fundació la Marató de TV3 (202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, drug delivery, and therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study

  • Bolufer Cardona, Monica
  • Blasco, Miquel
  • Quintana, Luis F
  • Rabasco, Cristina
  • Shabaka, Amir
  • García-Carro, Clara
Kidney biopsy; Renal pathology; Solid organ neoplasm, Biòpsia renal; Patologia renal; Neoplàsia d'òrgans sòlids, Biopsia renal; Patología renal; Neoplasia de órganos sólidos, Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, Río Hortega CM20/00111, PI17/00257, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, and RD21/0005/0016 (RICORS 2040).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

  • León-Román, Juan
  • Bolufer Cardona, Monica
  • Sánchez-Salinas, Mario
  • Alonso-Martínez, Carla
  • Bestard, Oriol
  • Bermejo García, Sheila
  • Cecilia del Carmen, Carpio Segura
  • Garcia-Carro, Clara
  • Barba, Pere
  • Soler, María José
  • IACOBONI, GLORIA
CAR-T therapy; Acute kidney injury; Onconephrology, Terapia CAR-T; Lesión renal aguda; Onconefrología, Teràpia CAR-T; Lesió renal aguda; Onconefrologia, Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients., P.B. received research funding from the Carlos III Health Institute (PI21/0199,INT23/00072), Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units

  • León-Román, Juan
  • Azancot Rivero, M Antonieta
  • Marouço, Catarina
  • Patricio-Liébana, Marc
  • Ramos Terrades, Natalia
  • Núñez Delgado, Sara
  • Zamora Carrillo, Jorge Ivan
  • TOAPANTA, NÉSTOR
  • Méndez Fernández, Ana Belén
  • Soler, María José
Cardiorenal syndrome; Chronic kidney disease; Heart failure, Síndrome cardiorrenal; Enfermedad renal crónica; Insuficiencia cardíaca, Síndrome cardiorenal; Malaltia renal crònica; Insuficiència cardíaca, Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this study is to evaluate the clinical performance of patients with CRS who are followed up by the Cardiorenal Unit (CRU). Methods: We conducted a retrospective observational study of patients referred to the CRU from April 1, 2022, to April 30, 2023. Demographics, laboratory and ultrasonographic tests, and outcomes were evaluated. Results: Fifty-four patients were seen in the CRU. A total of 45 (83%) and 16 (30%) patients completed follow-up in the CRU at 6 and 12 months, respectively. The mean age was 70 years ± 1.6, and 65% were men. Almost 50% of patients had ischemic heart disease-related HF. The mean cardiac ejection fraction (EF) was 40% ± 1.6, and 61% of patients had HF with reduced EF (HFrEF). NYHA functional classes II and III were the most frequent (60% and 35%, respectively). At 6 months after follow-up, treatment was optimized with sacubitril-valsartan in 33% vs. 49% (p = 0.02) and SGLT2 inhibitors in 48% vs. 72% (p = 0.008), without significant deterioration in renal function (creatinine: p = 0.61; eGFR: p = 0.19). There was also a reduction of more than 50% in the number of hospital admissions (p = 0.002). A total of 22% required peritoneal dialysis, and 20% required hemodialysis. Ten (19%) patients died, five of them due to cardiovascular (CV) events. Conclusions: The CRU is vital for the management of complex patients as it ensures the implementation of medications that reduce CV mortality and decrease the number of hospital admissions in HF., This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, Grant No. PI21/01292, PI24/01510, ERA PerMed JTC2022 Grant No. AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas, PI23/01209 Proyectos de I+D+I en Salud AES2023.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).